These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36406945)

  • 1. Type 5 Cardiorenal Syndrome: An Underdiagnosed and Underrecognized Disease Process of the American Mother.
    Ilagan J; Sahani H; Saleh AB; Tavakolian K; Mararenko A; Udongwo N; Douedi S; Upadhyaya V; Patel S; Mushtaq A; Sealove B; Gonzalez D; Asif A
    J Clin Med Res; 2022 Oct; 14(10):395-399. PubMed ID: 36406945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence based review of management of cardiorenal syndrome type 1.
    Ong LT
    World J Methodol; 2021 Jul; 11(4):187-198. PubMed ID: 34322368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management.
    Verma D; Firoz A; Garlapati SKP; Sai Charaan Reddy Sathi T; Haris M; Dhungana B; Ray B; Shah G; Kc B; Paudel P
    Cureus; 2021 Aug; 13(8):e17240. PubMed ID: 34540466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiorenal Syndrome.
    Ricci Z; Romagnoli S; Ronco C
    Crit Care Clin; 2021 Apr; 37(2):335-347. PubMed ID: 33752859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein biomarkers for cardiorenal syndrome.
    Petra E; Zoidakis J; Vlahou A
    Expert Rev Proteomics; 2019 Apr; 16(4):325-336. PubMed ID: 30855192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiorenal syndrome.
    Ronco C; Di Lullo L
    Heart Fail Clin; 2014 Apr; 10(2):251-80. PubMed ID: 24656104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of serelaxin in acute heart failure.
    Du XJ; Hewitson TD; Nguyen MN; Samuel CS
    Circ J; 2014; 78(3):542-52. PubMed ID: 24451687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Cardiorenal Syndrome in Heart Failure: from Dogmas to Advances.
    Tang WHW; Kiang A
    Curr Cardiol Rep; 2020 Sep; 22(11):143. PubMed ID: 32910296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
    Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
    Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiorenal syndrome in critical care: the acute cardiorenal and renocardiac syndromes.
    Cruz DN
    Adv Chronic Kidney Dis; 2013 Jan; 20(1):56-66. PubMed ID: 23265597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental Cardiorenal Syndrome Type 3: What Is Known so Far?
    Patschan D; Marahrens B; Jansch M; Patschan S; Ritter O
    J Clin Med Res; 2022 Jan; 14(1):22-27. PubMed ID: 35211213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.
    Wolf VL; Phillips TL; Taylor EB; Sasser JM; Ryan MJ
    Am J Physiol Heart Circ Physiol; 2019 Aug; 317(2):H234-H242. PubMed ID: 31125285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiorenal Syndrome in Western Countries: Epidemiology, Diagnosis and Management Approaches.
    Ronco C; Di Lullo L
    Kidney Dis (Basel); 2017 Jan; 2(4):151-163. PubMed ID: 28232932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial.
    Corcoran D; Radjenovic A; Mordi IR; Nazir SA; Wilson SJ; Hinder M; Yates DP; Machineni S; Alcantara J; Prescott MF; Gugliotta B; Pang Y; Tzemos N; Semple SI; Newby DE; McCann GP; Squire I; Berry C
    Cardiovasc Res; 2021 Jan; 117(1):320-329. PubMed ID: 32065620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New aspects in cardiorenal syndrome and HFpEF.
    Méndez AB; Azancot MA; Olivella A; Soler MJ
    Clin Kidney J; 2022 Oct; 15(10):1807-1815. PubMed ID: 36158149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour.
    Weiss G; Teichman S; Stewart D; Nader D; Wood S; Breining P; Unemori E
    BMC Pregnancy Childbirth; 2016 Sep; 16(1):260. PubMed ID: 27596360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1.
    Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM
    Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528
    [No Abstract]   [Full Text] [Related]  

  • 18. Serelaxin attenuates renal inflammation and fibrosis in a mouse model of dilated cardiomyopathy.
    Giam B; Chu PY; Kuruppu S; Smith AI; Horlock D; Murali A; Kiriazis H; Du XJ; Kaye DM; Rajapakse NW
    Exp Physiol; 2018 Dec; 103(12):1593-1602. PubMed ID: 30311699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiorenal Syndromes: Evaluation and Management.
    Fowler LH; McAtee C
    Crit Care Nurs Clin North Am; 2022 Dec; 34(4):383-393. PubMed ID: 36336429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
    Kumar VA; Wilson SS; Ayaz SI; Levy PD
    Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.